Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cellectar Biosciences, Inc. (CLRB : NSDQ)

• Company Description    Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $4.93 Daily Weekly Monthly 20 Day Moving Average: 164,670 shares Shares Outstanding: 1.81 (millions) Market Capitalization: $8.92 (millions) Beta: 0.51 52 Week High: $94.50 52 Week Low: $4.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -62.43% -63.84% 12 Week -45.09% -53.82% Year To Date -45.09% -48.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 CAMPUS DRIVE - FLORHAM PARK,NJ 07932 USA ph: 608-441-8120 fax: 608-441-8121 investors@cellectar.com http://www.cellectar.com

• General Corporate Information    Officers JamesV.Caruso - ChiefExecutiveOfficer and Director Chad J. Kolean - ChiefFinancialOfficer Frederick W. Driscoll - Director Asher Alban Chanan-Khan - Director Stefan D. Loren - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 15117F880 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 1.81 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.51 Market Capitalization: $8.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-14.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.98 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 67.50% vs. Previous Quarter: -1,200.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -619.70 12/31/24 - -1,259.79 ROA 06/30/25 - - 03/31/25 - -158.04 12/31/24 - -142.65 Current Ratio 06/30/25 - - 03/31/25 - 2.47 12/31/24 - 2.58 Quick Ratio 06/30/25 - - 03/31/25 - 2.47 12/31/24 - 2.58 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.04 12/31/24 - 8.98 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 14.34 12/31/24 - 8.82

Powered by Zacks Investment Research ©